sellModerate cluster of 310b5-1 plan
Hopkinson Craig C. sold $2.0M of ALKS
EVP R&D, Chief Medical Officer at Alkermes plc.. 61,151 shares at an average of $32.07, traded Dec 9, 2024, filed Dec 9, 2024.
Warning score
40Value
$2.0M
61,151 shares
Holdings after
47,576
-56% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price, last year
Rows in this filing
Every transaction in Form 4 0001127602-24-028885, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | MOption exercise Ordinary Shares10b5-1 | +12,452 | $20.03 | $249k | 72,182 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Ordinary Shares10b5-1 | +12,090 | $19.34 | $234k | 84,272 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Ordinary Shares10b5-1 | +12,044 | $24.59 | $296k | 96,316 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Ordinary Shares10b5-1 | +12,411 | $26.82 | $333k | 108,727 | Dec 9, 2024 |
| Dec 9, 2024 | SOpen-market sale Ordinary Shares10b5-1 | -61,151 | $32.07 | $2.0M | 47,576 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -12,452 | $0.00 | $0 | 116,722 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -12,090 | $0.00 | $0 | 188,323 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -12,044 | $0.00 | $0 | 130,300 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -12,411 | $0.00 | $0 | 110,616 | Dec 9, 2024 |
Related signals
Other insiders at Alkermes plc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 0Weak | sell10b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $66k | 1,938 | |
| 9Weak | sell 210b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $132k | 3,743 | |
| 0Weak | sell 210b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $47k | 1,327 | |
| 33Weak | sell 210b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $12M | 349,340 | |
| 25Weak | sell10b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $3.2M | 100,918 | |
| 9Weak | sell 310b5-1 | ALKS Alkermes plc. | LAURENCIN CATO T director | $86k | 2,691 | |
| 29Weak | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $290k | 9,221 | |
| 32Weak | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $442k | 14,349 | |
| 21Weak | sell 310b5-1 | ALKS Alkermes plc. | Nichols Christian Todd SVP, Chief Commercial Officer | $152k | 5,208 | |
| 15Weak | sell10b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $1.8M | 58,996 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.